302 related articles for article (PubMed ID: 22294456)
41. Dendritic cell subsets.
Macri C; Pang ES; Patton T; O'Keeffe M
Semin Cell Dev Biol; 2018 Dec; 84():11-21. PubMed ID: 29246859
[TBL] [Abstract][Full Text] [Related]
42. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. exploiting cross-priming.
Arina A; Tirapu I; Alfaro C; Rodríguez-Calvillo M; Mazzolini G; Inogés S; López A; Feijoo E; Bendandi M; Melero I
Exp Hematol; 2002 Dec; 30(12):1355-64. PubMed ID: 12482496
[TBL] [Abstract][Full Text] [Related]
43. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells.
Koyama M; Hashimoto D; Aoyama K; Matsuoka K; Karube K; Niiro H; Harada M; Tanimoto M; Akashi K; Teshima T
Blood; 2009 Feb; 113(9):2088-95. PubMed ID: 19144988
[TBL] [Abstract][Full Text] [Related]
44. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
45. Harnessing Dendritic Cells for Poly (D,L-lactide-
Koerner J; Horvath D; Groettrup M
Front Immunol; 2019; 10():707. PubMed ID: 31024545
[TBL] [Abstract][Full Text] [Related]
46. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation.
Jähn PS; Zänker KS; Schmitz J; Dzionek A
Cell Immunol; 2010; 265(1):15-22. PubMed ID: 20673884
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
48. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology.
Lombardi VC; Khaiboullina SF
Clin Immunol; 2014 Jul; 153(1):165-77. PubMed ID: 24769378
[TBL] [Abstract][Full Text] [Related]
49. The Syk-Coupled C-Type Lectin Receptors Dectin-2 and Dectin-3 Are Involved in
Preite NW; Feriotti C; Souza de Lima D; da Silva BB; Condino-Neto A; Pontillo A; Calich VLG; Loures FV
Front Immunol; 2018; 9():464. PubMed ID: 29616019
[TBL] [Abstract][Full Text] [Related]
50. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
51. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
52. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
Wu J; Li S; Yang Y; Zhu S; Zhang M; Qiao Y; Liu YJ; Chen J
Oncotarget; 2017 Feb; 8(7):11708-11718. PubMed ID: 28052019
[TBL] [Abstract][Full Text] [Related]
53. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
[TBL] [Abstract][Full Text] [Related]
54. Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity.
Palma G; De Laurenzi V; De Marco M; Barbieri A; Petrillo A; Turco MC; Arra C
Biochim Biophys Acta; 2012 Dec; 1826(2):407-14. PubMed ID: 22579960
[TBL] [Abstract][Full Text] [Related]
55. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.
Fonteneau JF; Gilliet M; Larsson M; Dasilva I; Münz C; Liu YJ; Bhardwaj N
Blood; 2003 May; 101(9):3520-6. PubMed ID: 12511409
[TBL] [Abstract][Full Text] [Related]
56. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
[TBL] [Abstract][Full Text] [Related]
57. Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid dendritic cell-dependent adaptive immunity.
Lousberg EL; Fraser CK; Tovey MG; Diener KR; Hayball JD
J Virol; 2010 Jul; 84(13):6549-63. PubMed ID: 20410285
[TBL] [Abstract][Full Text] [Related]
58. Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications.
Fucikova J; Palova-Jelinkova L; Bartunkova J; Spisek R
Front Immunol; 2019; 10():2393. PubMed ID: 31736936
[TBL] [Abstract][Full Text] [Related]
59. Dendritic cells: still a promising tool for cancer immunotherapy.
Aragoneses-Fenoll L; Corbí AL
Clin Transl Oncol; 2007 Feb; 9(2):77-82. PubMed ID: 17329218
[TBL] [Abstract][Full Text] [Related]
60. Dendritic cells: limited potential in immunotherapy.
Soruri A; Zwirner J
Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
